Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This proposal translates a hypothesis driven basic research into clinical setting to
determine the potential of using autologous CD133+ cells to reverse fibrosis and improve
clinical outcome for patients with end stage cirrhosis. This has significant impact on the
management of cirrhosis.
Phase:
Phase 3
Details
Lead Sponsor:
National University Hospital, Singapore
Collaborators:
Changi General Hospital Singapore General Hospital Tan Tock Seng Hospital